Prevention of relapses in systemic lupus erythematosus
- 1 June 1995
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 345 (8965) , 1595-1599
- https://doi.org/10.1016/s0140-6736(95)90114-0
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Derivation of the sledai. A disease activity index for lupus patientsArthritis & Rheumatism, 1992
- Outcome of Systemic Lupus Erythematosus a Study of 66 Patients over 7 Years with Special Reference to the Predictive Value of Anti-DNA Antibody DeterminationsScandinavian Journal of Rheumatology, 1991
- Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosusClinical and Experimental Immunology, 1990
- Measurement of increases in anti‐double‐stranded dna antibody levels as a predictor of disease exacerbation in systemic lupus erythematosusArthritis & Rheumatism, 1990
- The first international standard for antibodies to double stranded DNA.Annals of the Rheumatic Diseases, 1988
- Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus ErythematosusNew England Journal of Medicine, 1988
- Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus.Annals of the Rheumatic Diseases, 1986
- Therapy of Lupus NephritisNew England Journal of Medicine, 1986
- Correlation between levels of DNA antibodies and clinical disease activity in SLE.Annals of the Rheumatic Diseases, 1977
- Longitudinal Studies of Anti-Dna Antibody Levels in SleScandinavian Journal of Rheumatology, 1975